ABSTRACT
A 72-year-old female with scirrhous-type advanced gastric cancer was treated with TS-1/CDDP as neoadjuvant chemotherapy. TS-1 (80 mg/m(2)/day) was orally administered for 3 weeks and CDDP (60 mg/m(2)) was administered by intravenous drip on day 8. Partial response (PR) was obtained after the first course, and total gastrectomy was performed. The histological diagnosis revealed complete disappearance of cancer cells in the stomach and a few regional lymph node metastases (3/67). The patient has now been in good health without a recurrence for 1 year and 9 months after surgery.
Subject(s)
Adenocarcinoma, Scirrhous/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gastrectomy , Lymph Nodes/pathology , Stomach Neoplasms/drug therapy , Adenocarcinoma, Scirrhous/secondary , Adenocarcinoma, Scirrhous/surgery , Aged , Cisplatin/administration & dosage , Drug Administration Schedule , Drug Combinations , Female , Humans , Lymphatic Metastasis , Neoadjuvant Therapy , Oxonic Acid/administration & dosage , Pyridines/administration & dosage , Remission Induction , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tegafur/administration & dosageABSTRACT
Protein-losing gastroenteropathy (PLG) can occur as a manifestation of various diseases including autoimmune disorders, and optimal therapy of these underlying diseases may be the only effective remedy for PLG. In the present report, we describe a case of a 54-year-old woman with PLG associated with an autoimmune disease, presumably CREST syndrome. She failed to respond to steroid treatment. Subsequently, cyclosporine was initiated, which resulted in a rapid recovery. The patient was successfully treated with low-dose cyclosporine for five years. There has not been, to our knowledge, any report of PLG successfully treated with cyclosporine. Cyclosporine therapy may be effective not only in inducing but also in maintaining complete remission in patients with autoimmune-associated PLG, especially refractory or intolerable to steroids and/or immunosuppressive therapies.
Subject(s)
CREST Syndrome/drug therapy , Cyclosporine/administration & dosage , Immunosuppressive Agents/administration & dosage , Protein-Losing Enteropathies/diagnosis , Protein-Losing Enteropathies/drug therapy , Administration, Oral , Biopsy, Needle , CREST Syndrome/complications , CREST Syndrome/diagnosis , CREST Syndrome/immunology , Dose-Response Relationship, Drug , Drug Administration Schedule , Duodenum/diagnostic imaging , Duodenum/pathology , Female , Follow-Up Studies , Humans , Immunohistochemistry , Long-Term Care , Middle Aged , Protein-Losing Enteropathies/complications , Protein-Losing Enteropathies/immunology , Radionuclide Imaging , Risk Assessment , Severity of Illness Index , Stomach/diagnostic imaging , Stomach/pathology , Treatment OutcomeSubject(s)
Abscess/complications , Colitis, Ulcerative/complications , Subcutaneous Tissue , Abscess/diagnosis , Adult , Female , HumansABSTRACT
Primary biliary cirrhosis is often associated with autoimmune diseases. However, an association between primary biliary cirrhosis and pernicious anemia has rarely been reported. We report a patient with primary biliary cirrhosis associated with pernicious anemia and autoimmune gastritis. The patient was a 64-year-old Japanese woman who had been diagnosed as having primary biliary cirrhosis 5 years previously. She was readmitted with jaundice and macrocytic anemia. The diagnosis of pernicious anemia was confirmed by the low level of serum vitamin B12 and the presence of anti-parietal cell antibody and anti-intrinsic factor antibody. Pernicious anemia should be regarded as a possible complication of primary biliary cirrhosis.
